Erythropoietin Blockade Inhibits Tumor Angiogenesis and Progression
Author Information
Author(s): Matthew E. Hardee, Yiting Cao, Ping Fu, Xiaohong Jiang, Yulin Zhao, Zahid N. Rabbani, Zeljko Vujaskovic, Mark W. Dewhirst, Murat O. Arcasoy
Primary Institution: Duke University Medical Center
Hypothesis
The study investigates the role of erythropoietin as an angiogenic factor that modulates tumor progression.
Conclusion
Erythropoietin is an important angiogenic factor that regulates tumor neovascularization and growth, and its blockade may serve as a potential therapeutic target in cancer.
Supporting Evidence
- Co-injection of erythropoietin with tumor cells significantly stimulated tumor neovascularization and growth.
- Expression of erythropoietin antagonist R103A-EPO inhibited angiogenesis and impaired tumor growth.
- Local treatment with erythropoietin resulted in a significant increase in tumor growth and vascular length density.
Takeaway
Erythropoietin helps tumors grow by making new blood vessels, but blocking it can stop the tumors from growing.
Methodology
Fluorescently-labeled rodent mammary carcinoma cells were injected into mice, and the effects of erythropoietin and its antagonists on tumor growth and angiogenesis were assessed using intravital microscopy.
Limitations
The study primarily uses an ectopic model which may not fully represent in vivo tumor behavior.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website